This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
zacks-consensus-estimate: Archive
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
CHRSNegative Net Change DTILPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Yext (YEXT) Q4 Earnings Beat Estimates
by Zacks Equity Research
Yext (YEXT) delivered earnings and revenue surprises of +7.69% and -1.14%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
YEXTNegative Net Change DUOTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Freightcar America (RAIL) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Freightcar America (RAIL) delivered earnings and revenue surprises of -11.11% and -13.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
RAILPositive Net Change ULHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Hewlett Packard Enterprise (HPE) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Hewlett Packard Enterprise (HPE) delivered earnings and revenue surprises of +10.17% and -0.25%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
HPEPositive Net Change MUNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Repay Holdings (RPAY) Lags Q4 Earnings Estimates
by Zacks Equity Research
Repay Holdings (RPAY) delivered earnings and revenue surprises of -13.64% and +2.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
RPAYPositive Net Change GDOTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Vail Resorts (MTN) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Vail Resorts (MTN) delivered earnings and revenue surprises of -3.12% and -2.68%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
MTNPositive Net Change THPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD (LFMD) delivered earnings and revenue surprises of -300.00% and +5.92%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
LFMDNegative Net Change SERANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -5.50% and +17.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
SEPNPositive Net Change KYNBNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stereotaxis (STXS) delivered earnings and revenue surprises of +5.21% and -5.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
STXSPositive Net Change NSPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
VYGRNegative Net Change GYRENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank